Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Launch of UPASITA\u00ae IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Crinetics Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$13.0 million","newsHeadline":"Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter Into Exclusive Licensing Agreement for The Development and Commercialization of Paltusotine in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Sanwa Kagaku Kenkyusho

    Menu

    Sanwa Kagaku Kenkyusho

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sanwa Kagaku Kenkyusho

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter Into Exclusive Licensing Agreement for The Development and Commercialization of Paltusotine in Japan

              Details:

              Paltusotine is Crinetics’ investigational, orally available nonpeptide somatostatin receptor type 2 (SST2) agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors (NETs), including NETs complicated by carcinoid syndrome.

              Lead Product(s): Paltusotine

              Therapeutic Area: Endocrinology Product Name: CRN00808

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Crinetics Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: $13.0 million

              Deal Type: Licensing Agreement February 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sanwa Kagaku Kenkyusho

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Launch of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

              Details:

              UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.

              Lead Product(s): Upacicalcet Sodium

              Therapeutic Area: Endocrinology Product Name: Upasita

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Kissei Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY